Pharma’s reputation stays low in 2013: PMLive

The reputation of pharma companies remained at a low ebb last year, with performance ratings down across the board compared to 2011, according to a survey of patient groups.

All told, 35 per cent of respondents to the PatientView poll indicated that multinational pharma companies had an « excellent » or « good reputation », around the same as in 2012 but down from 41 per cent in 2011.

Once again, the drug industry ranked second bottom among healthcare industries just ahead of for-profit health insurers, while biotech companies also slipped down the rankings a little.

« Pharma should worry about patients’ views of its corporate reputation, » said Alex Wyke, PatientView’s chief executive.

See on www.pmlive.com